IR News

Lateset Result

FY2024 (3Q)
PDF Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2024 (JGAAP) （209KB）
FY2024 (2Q)
PDF Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2024 (JGAAP) （214KB）
FY2024 (1Q)
PDF Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2024 (JGAAP) （208KB）
FY2023
PDF Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (JGAAP) （307KB）
FY2023 (3Q)
PDF Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2023 (JGAAP) （207KB）
FY2023 (2Q)
PDF Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2023 (JGAAP) （233KB）
FY2023 (1Q)
PDF Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2023 (JGAAP) （230KB）
FY2022
PDF Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (JGAAP) （311KB）
FY2022 (3Q)
PDF Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2022 (JGAAP) （248KB）
FY2022 (2Q)
PDF Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (JGAAP) （231KB）
FY2022 (1Q)
PDF Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2022 (JGAAP) （226KB）
FY2021
PDF (Delayed)Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP) （307KB）
FY2021 (3Q)
PDF Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2021 (JGAAP) （218KB）
FY2021 (2Q)
PDF Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (JGAAP) （242KB）
FY2021 (1Q)
PDF Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2021 (JGAAP) （225KB）

CEO's Message :
To Our Shareholders and Investors

We are committed to providing patients with novel medicines as rapidly as possible as we continue to improve shareholder value and strengthen management.